studies

breast cancer (BC), neratinib plus capecitabine vs. platinum derivate, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 1314